Every Form 4 that Lixte Biotechnology Holdings, Inc. (LIXT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LIXT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIXT filings page.
Stazzone Peter reported acquisition or exercise transactions in this Form 4 filing.
LIXTE Biotechnology Holdings, Inc. reported that its Chief Financial Officer, Peter Stazzone, received an equity award of 50,000 shares of common stock on a grant or award basis, at a price of $0.00 per share. This award corresponds to 50,000 restricted share units (RSUs) that vest into one share of common stock each.
The footnotes state that these 50,000 RSUs vested after the achievement of performance conditions in the RSU agreement under the company’s 2020 Stock Incentive Plan. Following this award, Column 5 of the Form 4 reflects a total of 100,000 RSUs attributed to the reporting person, including the 50,000 newly awarded RSUs and 50,000 previously held RSUs, all of which have vested.
Sawyer Jason David reported acquisition or exercise transactions in this Form 4 filing.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Jason David Sawyer received an equity award of 40,000 restricted stock units (RSUs). The grant was made under the company’s 2020 Stock Incentive Plan after performance conditions in his RSU agreement were satisfied. Following this award, he holds 65,000 RSUs, all of which have vested.
Lixte Biotechnology Holdings CEO Geordan Garrett Pursglove reported an acquisition of equity-based compensation through restricted share units. On July 1, 2026, he received 350,000 RSUs at a stated price of $0.00 per share as a grant or award.
Each RSU represents a right to receive one share of common stock upon vesting, tied to continued service and performance conditions that have already been satisfied. After this award, his reported holdings total 700,000 RSUs, including the 350,000 newly awarded RSUs and 350,000 RSUs that have fully vested.
Primus Guy Warren reported acquisition or exercise transactions in this Form 4 filing.
Lixte Biotechnology Holdings director Guy Warren Primus received 15,000 restricted stock units (RSUs) as an equity award. The RSUs were granted under the company’s 2020 Stock Incentive Plan at no cash cost and vest upon achievement of performance conditions, which have already been satisfied.
After this award, Primus reports a total of 40,000 RSUs, including 25,000 previously granted RSUs that have vested. This is a compensation-related grant rather than an open-market share purchase or sale.
Holloway Michael Andrew reported acquisition or exercise transactions in this Form 4 filing.
Lixte Biotechnology Holdings director Michael Andrew Holloway received an equity award of 15,000 restricted share units (RSUs). The RSUs were granted under the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan and an applicable RSU agreement.
Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 15,000 RSUs vested after the performance conditions in his RSU agreement were satisfied. Following this award, the total reported in his holdings is 40,000 RSUs, consisting of the 15,000 new RSUs and 25,000 previously granted RSUs, all of which have vested.
Felix Lourdes reported acquisition or exercise transactions in this Form 4 filing.
LIXTE Biotechnology Holdings director Felix Lourdes received a grant of 30,000 restricted share units (RSUs) under the company’s 2020 Stock Incentive Plan. The RSUs represent the right to receive an equal number of common shares upon vesting, and the performance conditions for these 30,000 RSUs have been satisfied.
After this award, Lourdes holds a total of 55,000 RSUs, including 25,000 RSUs that have already vested. The grant was a compensation award with no cash paid per share.
Porter Stuart D reported acquisition or exercise transactions in this Form 4 filing.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Stuart D. Porter reported receiving an equity grant of 25,000 shares of common stock in the form of restricted share units. The grant was made at a stated price of $0.00 per share, reflecting stock-based compensation rather than a market purchase.
The 25,000 RSUs were granted under the company’s 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The RSUs vest 25% on May 29, 2026, and 25% on the last date of each subsequent calendar quarter until fully vested. Following this grant, Porter directly holds 25,000 shares.
Lixte Biotechnology CEO Geordan Garrett Pursglove restructured his equity compensation on April 15, 2026. He agreed to cancel 350,000 options to purchase common stock with a $2.83 exercise price that were scheduled to expire on July 3, 2030, returning them to the company.
In exchange, he received 350,000 shares of common stock as a grant or award tied to 350,000 restricted share units under the 2020 Stock Incentive Plan. These RSUs vest immediately upon grant, so he now directly holds 350,000 common shares after the transaction. The filing shows no open‑market buying or selling; it is an issuer disposition of options paired with a compensatory stock award.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Chief Financial Officer Peter Stazzone restructured his equity compensation on April 15, 2026. He agreed to cancel 50,000 stock options with a $4.45 exercise price in exchange for 50,000 restricted stock units granted the same day.
Each RSU represents a contingent right to receive one share of common stock, and all 50,000 RSUs vested immediately upon grant, leaving him with 50,000 shares of common stock held directly after the transactions. No open‑market buying or selling occurred; these were compensation-related adjustments between the executive and the company.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Felix Lourdes entered into a Stock Option Cancellation Agreement on April 15, 2026. The company canceled 25,000 stock options with a $4.05 exercise price that had been granted on December 24, 2025 and, in exchange, granted 25,000 restricted share units (RSUs).
Each RSU represents a right to receive one share of common stock upon vesting, and all 25,000 RSUs vested immediately on the grant date. Following these compensation-related transactions, Lourdes directly holds 25,000 shares of common stock, with no remaining options from the canceled grant.
Director Jason David Sawyer reported a compensation-related change in his equity awards in LIXTE BIOTECHNOLOGY HOLDINGS, INC. On April 15, 2026, he agreed with the company to cancel 25,000 options to purchase common stock with a $3.59 exercise price, which otherwise would have vested over time. In exchange, he received 25,000 restricted share units (RSUs), each representing a contingent right to one share of common stock. The RSUs were granted under the company’s 2020 Stock Incentive Plan and vested immediately upon grant, resulting in 25,000 shares of common stock held directly after the transactions. This sequence is a restructuring of equity compensation rather than an open-market buy or sell.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Michael Andrew Holloway restructured his equity compensation on April 15, 2026. He disposed of options to purchase 25,000 shares of common stock back to the company and, in exchange, received 25,000 restricted share units (RSUs).
Each RSU represents a right to receive one share of common stock, and all 25,000 RSUs vested immediately upon grant, subject to continued service conditions in the plan documents. Following these transactions, Holloway directly holds 25,000 shares of common stock, reflecting this grant-and-cancel structure rather than an open-market trade.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. director Guy Warren Primus exchanged equity awards on April 15, 2026. The company canceled 25,000 stock options with a $4.05 exercise price and, under a Stock Option Cancellation Agreement, granted 25,000 restricted share units that vest immediately, giving him 25,000 shares of common stock directly owned after the transaction.